MindMed announces its year-end results for 2020, cash-on-hand at US$161 million, including a total cash burn for 2020 of US$24.2 million.
Exploring the companies and themes that make up this emerging and exciting new sector
Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe
Cybin announces senior management changes as it moves into the next stage of its evolution.
The First Psychedelic Medicine Clinic Opens in Minnesota
The growing rates of depression, anxiety, and other mental health illnesses have contributed to a national mental health crisis in the United States and call for new and unconventional treatment options.
The COVID Conundrum For Psychedelic Stocks
The COVID pandemic is making the need for psychedelic drugs and the commercial potential of the industry much greater. But there is a catch.
Traumatic Brain Injury (TBI): Six Psychedelics Companies Target $120 Billion Market
One huge market. Six horses in the race (so far). Lots of prize money to go around.
Catalent Signs Drug Development Agreement with Cybin Inc for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
Cybin inks a drug development agreement with Catalent, "the leading global provider" of drug delivery, development and manufacturing solutions.
COMPASS Pathways granted two US patents
Compass is granted two psilocybin formulation patents, for treatment-resistant depression and major depressive disorder.
Investing in Psychedelics with MindMed Stock
It was the late Robin Williams who once said, “Reality is just a crutch for people who can’t handle drugs.”
Psychedelic Drugs: The Miracle Drugs of the 21st Century
Are psychedelics "miracle drugs"? If we compare them to the first Miracle Drug, the answer seems to be "yes".
MindMed Announces Inclusion in FTSE Russell Indexes
MindMed has been added to the FTSE Global Micro-Cap Index and the FTSE Total-Cap Index.
Andrew Yang Urges Legalization Of Psilocybin And Marijuana At New York City Mayoral Forum
Andrew Yang, a former 2020 Democratic presidential candidate who is now running for mayor of New York City, said in a recent campaign forum that he supports legalizing psilocybin and marijuana.
Top Psychedelic Penny Stocks To Watch After Latest Big Pharma Deal
Psychedelic Penny Stocks Continue Gaining Ground Among Mainstream Investors